29 results on '"Wörns, Marcus A."'
Search Results
2. Structured Early detection of Asymptomatic Liver Cirrhosis: Results of the population-based liver screening program SEAL
- Author
-
Labenz, Christian, Arslanow, Anita, Nguyen-Tat, Marc, Nagel, Michael, Wörns, Marcus-Alexander, Reichert, Matthias Christian, Heil, Franz Josef, Mainz, Dagmar, Zimper, Gundula, Römer, Barbara, Binder, Harald, Farin-Glattacker, Erik, Fichtner, Urs, Graf, Erika, Stelzer, Dominikus, Van Ewijk, Reyn, Ortner, Julia, Velthuis, Louis, Lammert, Frank, and Galle, Peter R.
- Published
- 2022
- Full Text
- View/download PDF
3. Outcomes in patients receiving palliative chemotherapy for advanced biliary tract cancer
- Author
-
Thol, Felix, Gairing, Simon Johannes, Czauderna, Carolin, Thomaidis, Thomas, Gamstätter, Thomas, Huber, Yvonne, Vollmar, Johanna, Lorenz, Johanna, Michel, Maurice, Bartsch, Fabian, Müller, Lukas, Kloeckner, Roman, Galle, Peter Robert, Wörns, Marcus-Alexander, Marquardt, Jens Uwe, Moehler, Markus, Weinmann, Arndt, and Foerster, Friedrich
- Published
- 2022
- Full Text
- View/download PDF
4. Impact of non-selective ß-blockers on hepatic encephalopathy in patients with liver cirrhosis
- Author
-
Labenz, Christian, Nagel, Michael, Toenges, Gerrit, Kuchen, Robert, Schattenberg, Jörn M., Hilscher, Max, Huber, Yvonne, Marquardt, Jens U., Labenz, Joachim, Galle, Peter R., and Wörns, Marcus-Alexander
- Published
- 2020
- Full Text
- View/download PDF
5. Higher scores in the Clinical Frailty Scale are associated with covert and overt hepatic encephalopathy in patients with cirrhosis.
- Author
-
Schleicher, Eva Maria, Kaps, Leonard, Schattenberg, Jörn M., Galle, Peter Robert, Wörns, Marcus-Alexander, Gairing, Simon Johannes, and Labenz, Christian
- Abstract
Frailty increases the vulnerability to internal and external stressors and may therefore be an indicator of a higher frequency of cirrhosis complications. We aimed to investigate the association of the Clinical Frailty Scale (CFS) with covert (CHE) and overt HE (OHE) development in patients with cirrhosis. This study analyzed data of 228 patients with cirrhosis. Frailty was assessed using CFS. Patients were examined for the presence of CHE (using PHES) at study inclusion and followed for OHE. Median CFS was 3 and 26 (11 %) patients were at least pre-frail (CFS>3). In multivariable logistic regression analysis in patients without a history of OHE (n = 195), a higher CFS was associated with the presence of CHE at baseline (OR 1.6, p = 0.039). During follow-up, 42 (18 %) patients developed an episode of OHE. In multivariable competing risk regression analyses, a higher CFS was independently associated with the development of an OHE episode in the total cohort (sHR 1.97, p < 0.001) and in the subcohort of patients without a history of OHE (sHR 1.88, p = 0.008). CFS appears to be a reliable tool to identify patients at higher risk of HE in whom intensified monitoring and treatment may be justified. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
6. Health-related quality of life in patients with compensated and decompensated liver cirrhosis
- Author
-
Labenz, Christian, Toenges, Gerrit, Schattenberg, Jörn M., Nagel, Michael, Huber, Yvonne, Marquardt, Jens U., Galle, Peter R., and Wörns, Marcus-Alexander
- Published
- 2019
- Full Text
- View/download PDF
7. Validation of the simplified Animal Naming Test as primary screening tool for the diagnosis of covert hepatic encephalopathy
- Author
-
Labenz, Christian, Beul, Larissa, Toenges, Gerrit, Schattenberg, Jörn M., Nagel, Michael, Sprinzl, Martin F., Nguyen-Tat, Marc, Zimmermann, Tim, Huber, Yvonne, Marquardt, Jens U., Galle, Peter R., and Wörns, Marcus-Alexander
- Published
- 2019
- Full Text
- View/download PDF
8. Recipient liver function before liver transplantation influences post-transplantation survival in patients with HCC
- Author
-
Foerster, Friedrich, Mittler, Jens, Darstein, Felix, Heise, Michael, Marquardt, Jens U., Wörns, Marcus-Alexander, Weinmann, Arndt, Sälter, Lina, Hoppe-Lotichius, Maria, Heinrich, Stefan, Kloeckner, Roman, Pitton, Michael B., Schattenberg, Jörn M., Sprinzl, Martin F., Düber, Christoph, Otto, Gerd, Lang, Hauke, Galle, Peter R., and Zimmermann, Tim
- Published
- 2018
- Full Text
- View/download PDF
9. WED-377 - Poorer results in the clinical frailty scale are associated with covert and overt hepatic encephalopathy in patients with cirrhosis
- Author
-
Schleicher, Eva Maria, Kaps, Leonard, Schattenberg, Jörn, Galle, Peter, Wörns, Marcus-Alexander, Gairing, Simon J., and Labenz, Christian
- Published
- 2023
- Full Text
- View/download PDF
10. WED-365 - A virtual reality-driving test to predict car accidents in patients with cirrhosis
- Author
-
Gairing, Simon Johannes, Schleicher, Eva Maria, Kaps, Leonard, Schulte-Beerbuehl, Sophia, Steiner, Kristina, Labenz, Joachim, Schattenberg, Jörn, Galle, Peter, Wörns, Marcus-Alexander, and Labenz, Christian
- Published
- 2023
- Full Text
- View/download PDF
11. Patient prioritisation in HCC treatment: All (good) things come in threes
- Author
-
Wörns, Marcus-Alexander and Galle, Peter Robert
- Published
- 2018
- Full Text
- View/download PDF
12. Validation of Clinical Scoring Systems ART and ABCR after Transarterial Chemoembolization of Hepatocellular Carcinoma.
- Author
-
Kloeckner, Roman, Pitton, Michael B., Dueber, Christoph, Schmidtmann, Irene, Galle, Peter R., Koch, Sandra, Wörns, Marcus A., and Weinmann, Arndt
- Abstract
Purpose: To perform an external validation of the Assessment for Retreatment with Transarterial Chemoembolization (ART) and α-fetoprotein (AFP), Barcelona Clinic Liver Cancer (BCLC), Child-Pugh, and response (ABCR) scores and to compare them in terms of prognostic power.Materials and Methods: From 2000 to 2015, 871 patients with hepatocellular carcinoma underwent transarterial chemoembolization at a tertiary referral hospital, and 176 met all inclusion and exclusion criteria for both scores and were analyzed. Nineteen percent (n = 34) had BCLC stage A disease and 81% had stage B disease. Thirty-nine patients (22%) presented with elevated AFP levels. Overall survival was calculated. Scores were validated and compared with a Harrell C-index, integrated Brier score (IBS), and prediction error curves.Results: Before the second chemoembolization procedure, 22 patients (12%) showed an increase of 1 point in Child-Pugh score and 51 patients (22%) had an increase of ≥ 2 points. Thirty-one patients (23%) showed a > 25% increase in aspartate aminotransferase level, and 114 (65%) showed a response to treatment. Consequently, 127 patients (72%) had a low ART score and 49 (28%) had a high ART score. One hundred fifty-eight patients (90%) had a low ABCR score, whereas 18 (10%) had a high ABCR score. Low and high ART score groups had median survival durations of 20.8 and 15.3 mo, respectively. Harrell C-indexes were 0.572 and 0.608, and IBSs were 0.135 and 0.128, for ART and ABCR, respectively. For both scores, an increase in Child-Pugh score ≥ 2 points and a radiologic response were significantly associated with survival.Conclusions: Both scores were of limited predictive value, and neither was sufficient to support clear-cut clinical decisions. Further effort is necessary to determine criteria for making valid clinical predictions. [ABSTRACT FROM AUTHOR]- Published
- 2017
- Full Text
- View/download PDF
13. Hepatic B cell leukemia-3 promotes hepatic steatosis and inflammation through insulin-sensitive metabolic transcription factors.
- Author
-
Gehrke, Nadine, Wörns, Marcus A., Huber, Yvonne, Hess, Moritz, Straub, Beate K., Hövelmeyer, Nadine, Waisman, Ari, Kim, Yong Ook, Schuppan, Detlef, Galle, Peter R., and Schattenberg, Jörn M.
- Subjects
- *
CARDIOVASCULAR diseases , *B cells , *FATTY liver , *INFLAMMATION , *NUCLEOTIDE sequence - Abstract
Background & Aims The pathomechanisms underlying non-alcoholic fatty liver disease (NAFLD) and the involved molecular regulators are incompletely explored. The nuclear factor-kappa B (NF-κB)-cofactor gene B cell leukemia-3 ( Bcl-3 ) plays a critical role in altering the transcriptional capacity of NF-κB – a key inducer of inflammation – but also of genes involved in cellular energy metabolism. Methods To define the role of Bcl-3 in non-alcoholic steatohepatitis (NASH), we developed a novel transgenic mouse model with hepatocyte-specific overexpression of Bcl-3 ( Bcl-3 Hep ) and employed a high-fat, high-carbohydrate dietary feeding model. To characterize the transgenic model, deep RNA sequencing was performed. The relevance of the findings was confirmed in human liver samples. Results Hepatocyte-specific overexpression of Bcl-3 led to pronounced metabolic derangement, characterized by enhanced hepatic steatosis from increased de novo lipogenesis and uptake, as well as decreased hydrolysis and export of fatty acids. Steatosis in Bcl-3 Hep mice was accompanied by an augmented inflammatory milieu and liver cell injury. Moreover, Bcl-3 expression decreased insulin sensitivity and resulted in compensatory regulation of insulin-signaling pathways. Based on in vivo and in vitro studies we identified the transcription factors PPARα, PPARγ and PGC-1α as critical regulators of hepatic metabolism and inflammation downstream of Bcl-3. Metformin treatment improved the metabolic and inflammatory phenotype in Bcl-3 Hep mice through modulation of PPARα and PGC-1α. Remarkably, these findings were recapitulated in human NASH, which exhibited increased expression and nuclear localization of Bcl-3. Conclusions In summary, Bcl-3 emerges as a novel regulator of hepatic steatosis, insulin sensitivity and inflammation in NASH. Lay summary Non-alcoholic fatty liver disease (NAFLD) is considered the most prevalent liver disease worldwide. Patients can develop end-stage liver disease resulting in liver cirrhosis or hepatocellular carcinoma, but also develop complications unrelated to liver disease, e.g., cardiovascular disease. Still there is no full understanding of the mechanisms that cause NAFLD. In this study, genetically engineered mice were employed to examine the role of a specific protein in the liver that is involved in inflammation and the metabolism, namely Bcl-3. By this approach, a better understanding of the mechanisms contributing to disease progression was established. This can help to develop novel therapeutic and diagnostic options for patients with NAFLD. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
14. Early changes in dynamic biomarkers of liver fibrosis in hepatitis C virus-infected patients treated with sofosbuvir.
- Author
-
Bernuth, Sebastian, Yagmur, Eray, Schuppan, Detlef, Sprinzl, Martin F., Zimmermann, Anca, Schad, Arno, Kittner, Jens M., Weyer, Veronika, Knapstein, Johanna, Schattenberg, Jörn M., Wörns, Marcus A., Galle, Peter R., and Zimmermann, Tim
- Abstract
Background Chronic hepatitis C is a major cause of liver-associated mortality caused by decompensated cirrhosis and hepatocellular carcinoma. With the approval of sofosbuvir, therapeutic efficacy has markedly increased. Early changes in non-invasive biomarkers of liver fibrosis under effective antiviral therapy are widely unknown. Aim To evaluate early changes of fibrosis markers determined by enhanced liver fibrosis (ELF) scores and liver stiffness measurement (FibroScan ® ) in patients treated with sofosbuvir. Methods A total of 32 hepatitis C patients treated prospectively with sofosbuvir were included. The ELF-panel and FibroScan measurements were performed at baseline, week 4, end-of-treatment and 12 weeks thereafter. Results Antiviral therapy resulted in a biochemical and virological response within 4 weeks. Sustained virological response rate at 12-week follow-up (SVR12) was 93.8%; there was a significantly decrease from baseline to 12-week post-treatment follow-up in ELF (10.00 vs. 9.37; p = 0.007) and FibroScan (8.0 vs. 6.8 kPa; p = 0.016) measurements, indicating improvement of the dynamics of liver fibrosis. Conclusion We observed a rapid decrease in non-invasive fibrosis markers measured by ELF-scores and FibroScan in hepatitis C-infected patients receiving sofosbuvir treatment. These initial results need to be histologically confirmed by liver biopsy in the future. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
15. Reply to: “Performance status in patients with HCC: New kid on the block”.
- Author
-
Wörns, Marcus-Alexander and Galle, Peter Robert
- Subjects
- *
LIVER cancer , *TUMOR classification , *LIVER transplantation , *PROGNOSIS - Published
- 2017
- Full Text
- View/download PDF
16. The impact of patient and tumour baseline characteristics on the overall survival of patients with advanced hepatocellular carcinoma treated with sorafenib.
- Author
-
Wörns, Marcus A., Koch, Sandra, Niederle, Ina M., Marquardt, Jens U., Nguyen-Tat, Marc, Gamstätter, Thomas, Schuchmann, Marcus, Schulze-Bergkamen, Henning, Galle, Peter R., and Weinmann, Arndt
- Abstract
Abstract: Background: Impact of patient and tumour baseline characteristics on the overall survival is not well characterized in patients with advanced hepatocellular carcinoma (HCC) treated with sorafenib. Aims/methods: Univariate/multivariate analyses were conducted to identify retrospectively the impact of baseline characteristics on the survival of 110 patients with advanced HCC treated with sorafenib. Results: Median survival of the whole cohort was 6.7 months, median survival in Child-Pugh A, B, C patients was 10.5, 6.1 and 3.0 months and median survival of patients with Barcelona Clinic Liver Cancer (BCLC) stage C/D was 6.8/2.6 months. Presence of ascites, presence of macrovascular invasion and BCLC stage D (mainly determined by Child-Pugh C status and Eastern Cooperative Oncology Group Performance Status>2) remained independent prognostic factors for the survival on multivariate analysis. Particularly, the presence of macrovascular invasion significantly influenced survival both in patients with liver cirrhosis Child-Pugh A and Child-Pugh B. Conclusion: Well maintained liver function and performance status are prerequisites for sorafenib treatment in patients with advanced HCC. Our findings do not support routine clinical use of sorafenib in Child-Pugh B patients. Evaluation of ascites and particularly macrovascular invasion might help to identify patients more likely to benefit from sorafenib treatment. [Copyright &y& Elsevier]
- Published
- 2013
- Full Text
- View/download PDF
17. The role of death effector domain-containing proteins in acute oxidative cell injury in hepatocytes
- Author
-
Schattenberg, Jörn M., Wörns, Marcus A., Zimmermann, Tim, He, You-Wen, Galle, Peter R., and Schuchmann, Marcus
- Subjects
- *
LIVER cells , *HOMEOSTASIS , *LIVER cancer , *LIVER failure , *OXIDATIVE stress , *MITOGEN-activated protein kinases - Abstract
Abstract: Apoptosis is a mechanism that regulates hepatic tissue homeostasis and contributes to both acute and chronic injury in liver disease. The apoptotic signaling cascade involves activation of the death-inducing signaling complex (DISC) and subsequent recruitment of proteins containing death effector domains (DED), which regulate downstream effector molecules. Prominent among these are the Fas-associated death domain (FADD) and the cellular caspase 8-like inhibitory protein (cFLIP), and alterations in these proteins can lead to severe disruption of physiological processes, including acute liver failure or hepatocellular carcinoma. Their role in cell signaling events independent of the DISC remains undetermined. Oxidative stress can cause cell injury from direct effects on molecules or by activating intracellular signaling pathways including the mitogen-activated protein kinases (MAPKs). In this context, prolonged activation of the cJun N-terminal kinase (JNK)/AP-1/cJun signaling pathway promotes hepatocellular apoptosis, whereas activation of the extracellular signal-regulated kinase (Erk) exerts protection. We investigated the roles of FADD and cFLIP in acute oxidant stress induced by the superoxide generator menadione in hepatocytes. Menadione resulted in dose-dependent predominantly necrotic cell death. Hepatocytes expressing a truncated, dominant-negative FADD protein were partially protected, whereas cFLIP-deficient hepatocytes displayed increased cell death from menadione. In parallel, Erk phosphorylation was enhanced in hepatocytes expressing dnFADD and decreased in cFLIP-deficient hepatocytes. Hepatocyte injury was accompanied by increased release of proapoptotic factors and increased JNK/cJun activation. Thus, FADD and cFLIP contribute to the regulation of cell death from acute oxidant stress in hepatocytes involving MAPK signaling. This implies that DED-containing proteins are involved in the regulation of cellular survival beyond their role in cell death receptor–ligand-mediated apoptosis. [Copyright &y& Elsevier]
- Published
- 2012
- Full Text
- View/download PDF
18. Sorafenib for recurrence of hepatocellular carcinoma after liver transplantation.
- Author
-
Weinmann, Arndt, Niederle, Ina Maria, Koch, Sandra, Hoppe-Lotichius, Maria, Heise, Michael, Düber, Christoph, Schuchmann, Marcus, Otto, Gerd, Galle, Peter Robert, and Wörns, Marcus-Alexander
- Subjects
LIVER cancer ,LIVER transplantation ,HEALTH outcome assessment ,RADIOTHERAPY ,IMMUNOSUPPRESSION ,RAPAMYCIN ,DIARRHEA ,CANCER relapse - Abstract
Abstract: Background: Recurrence of hepatocellular carcinoma after orthotopic liver transplantation not amenable to surgical approaches is associated with poor outcome. Aims: Retrospective evaluation of the safety and efficacy of sorafenib in patients with post-transplant hepatocellular carcinoma recurrence. Methods: Patients with post-transplant hepatocellular carcinoma recurrence were treated with sorafenib. Adverse events were assessed using National Cancer Institute Common Toxicity Criteria of AEs version 3.0, tumour response was evaluated according to Response Evaluation Criteria in Solid Tumours. Results: First-line therapy after recurrence was surgery (n =6), radiation therapy (n =1), chemotherapy (n =1), and sorafenib (n =3). Finally, 11 patients were treated with sorafenib. Nine patients (82%) received an additionally targeted therapy with sirolimus as part of their immunosuppressive regimen. Most common grade 3 adverse events included diarrhoea (46%), hand-foot skin reaction (27%), nausea, fatigue, and leucopoenia (all 18%). Sorafenib had to be discontinued in two patients due to adverse events and six additional patients required a dose adjustment. No deterioration of liver graft function occurred. Median time to progression was 4.1months; however, patients were treated with ongoing sorafenib in case of clinical benefit (median 8.9months). Median overall survival after initiation of sorafenib treatment was 20.1months. Conclusion: Sorafenib in combination with immunosuppression including sirolimus may be administered to patients with post-transplant hepatocellular carcinoma recurrence with acceptable toxicity and without deterioration of liver graft function. [Copyright &y& Elsevier]
- Published
- 2012
- Full Text
- View/download PDF
19. Reply to: “Response to ‘the flexible therapeutic approach to the BCLC B stage’: Time for scoring systems?”.
- Author
-
Foerster, Friedrich, Wörns, Marcus-Alexander, and Galle, Peter Robert
- Subjects
- *
LIVER cancer , *LIVER cancer prevention , *LIVER cancer patients - Abstract
The article presents views of critic on researchers study on therapeutic strategies for intermediate stage hepatocellular carcinoma (HCC). The critic mentions thatsome (Barcelona Clinic Liver Cancer) BCLCB patients would not benefit from the transarterial chemoembolization (TACE) and suggests therapeutic approaches such as immunotherapy.
- Published
- 2018
- Full Text
- View/download PDF
20. Sa1498 - Pharmacokinetics and Safety of Glecaprevir/Pibrentasvir in Adults with Chronic Genotype 1-6 Hepatitis C Virus Infection and Compensated Cirrhosis: An Integrated Analysis.
- Author
-
Gane, Edward, Poordad, Fred, Valdes, Joaquin M., Lin, Chih-Wei, Liu, Wei, Asatryan, Armen, Wang, Stanley, Stedman, Catherine A., Greenbloom, Susan, Nguyen, Tuan T., Elkhashab, Magdy, Wörns, Marcus-Alexander, Tran, Albert, Mulkay, Jean-Pierre, Yu, Yao, Porcalla, Ariel R., and Mensa, Federico
- Published
- 2017
- Full Text
- View/download PDF
21. Role of the GALAD and BALAD-2 Serologic Models in Diagnosis of Hepatocellular Carcinoma and Prediction of Survival in Patients.
- Author
-
Berhane, Sarah, Toyoda, Hidenori, Tada, Toshifumi, Kumada, Takashi, Kagebayashi, Chiaki, Satomura, Shinji, Schweitzer, Nora, Vogel, Arndt, Manns, Michael P., Benckert, Julia, Berg, Thomas, Ebker, Maria, Best, Jan, Dechêne, Alexander, Gerken, Guido, Schlaak, Joerg F., Weinmann, Arndt, Wörns, Marcus A., Galle, Peter, and Yeo, Winnie
- Abstract
Background & Aims GALAD and BALAD-2 are statistical models for estimating the likelihood of the presence of hepatocellular carcinoma (HCC) in individual patients with chronic liver disease and the survival of patients with HCC, respectively. Both models use objective measures, particularly the serum markers α-fetoprotein (AFP), AFP-L3, and des-γ-carboxyprothrombin. We aimed to validate these models in an international cohort of patients with HCC and assess their clinical performance. Methods We collected data on cancer diagnosis and outcomes of 6834 patients (2430 with HCC and 4404 with chronic liver disease) recruited from Germany, Japan, and Hong Kong. We also collected data from 229 patients with other hepatobiliary tract cancers (cholangiocarcinoma or pancreatic adenocarcinoma) and 92 healthy individuals (controls). For reference, the original UK cohort (on which the GALAD model initially was built and BALAD-2 was validated) was included in the analysis. We assessed the effects of tumor size and etiology on GALAD model performance, and its ability to correctly discriminate HCC from other hepatobiliary cancers. We assessed the performance of BALAD-2 in patients with different stages of HCC. Results In all cohorts, the area under the receiver operating characteristic curve (AUROC), quantifying the ability of GALAD to discriminate patients with HCC from patients with chronic liver disease, was greater than 0.90—similar to the series on which the model originally was built (AUROC, 0.97). GALAD discriminated patients with HCC from those with other hepatobiliary cancers with an AUROC value of 0.95; values were slightly lower for patients with small unifocal HCCs, ranging from 0.85 to 0.95. Etiology and treatment of chronic viral hepatitis had no effect on the performance of this model. BALAD-2 analysis assigned patients with HCC to 4 distinct prognostic groups—overall and when patients were stratified according to disease stage. Conclusions We validated the performance of the GALAD and BALAD-2 models for the diagnosis of HCC and predicting patient survival, respectively (based on levels of the serum markers AFP, AFP-L3, and des-γ-carboxyprothrombin), in an international cohort of almost 7000 patients. These systems might be used in HCC surveillance and determination of patient prognosis. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
22. Future perspectives in hepatocellular carcinoma.
- Author
-
Wörns, Marcus A. and Galle, Peter R.
- Subjects
LIVER cancer ,CIRRHOSIS of the liver ,CARCINOGENESIS ,CELLULAR signal transduction ,SURGICAL excision ,MEDICAL lasers ,CLINICAL medicine - Abstract
Abstract: Hepatocellular carcinoma (HCC) is one of the most common and lethal malignancies worldwide. Due to late diagnosis and advanced underlying liver cirrhosis, only limited treatment options with marginal clinical benefits have been available in up to 70% of patients. However, major progress has been achieved with regard to surveillance, early diagnosis, and multimodal treatment approaches during the last years leading to an improvement in prognosis. Particularly, the increasing knowledge of molecular hepatocarcinogenesis today provides the opportunity for targeted therapy. The multikinase inhibitor sorafenib has broadened the therapeutic horizon for patients with advanced disease and is currently under investigation for patients in early and intermediate stages as adjuvant therapy after resection/local ablation or in combination with transcatheter arterial chemoembolization. Future research will continue to unravel the key signaling cascades in different subclasses of HCC patients according to their genomic and proteomic profiling. These approaches bear the potential to individualize anticancer therapy, in the end allowing treatment of those benefiting most and excluding those who do not. This article shortly reviews the current knowledge in the management of HCC and provides insights into future perspectives with a special focus on recent progress in multidisciplinary treatment modalities. [Copyright &y& Elsevier]
- Published
- 2010
- Full Text
- View/download PDF
23. Ablation of c-FLIP in hepatocytes enhances death-receptor mediated apoptosis and toxic liver injury in vivo
- Author
-
Schattenberg, Jörn M., Zimmermann, Tim, Wörns, Marcus, Sprinzl, Martin F., Kreft, Andreas, Kohl, Tobias, Nagel, Michael, Siebler, Jürgen, Bergkamen, Henning Schulze, He, You-Wen, Galle, Peter R., and Schuchmann, Marcus
- Subjects
- *
LIVER cells , *APOPTOSIS , *ALANINE aminotransferase , *PROTEINS , *LIVER cancer , *LIPOPOLYSACCHARIDES , *TUMOR necrosis factors - Abstract
Background & Aims: Apoptosis is crucially involved in acute and chronic liver injury, including viral, cholestatic, toxic, and metabolic liver disease. Additionally, dysregulation of apoptosis signaling pathways has been implicated in hepatocarcinogenesis. The most prominent members of the apoptosis-mediating tumor necrosis factor receptor superfamily are the TNF-R1 (CD120a) and the CD95 (Apo-1/Fas) receptor. Although extensively studied, the intracellular signaling events in hepatocytes are only incompletely understood. Methods: To examine the role of the caspase-8 homolog cellular FLICE-inhibitory protein (c-FLIP) in liver injury, we generated mice with hepatocyte specific deletion of c-FLIP. Three models of acute liver injury were employed: the agonistic anti-CD95 antibody Jo2, d-galactosamine and LPS (GalN/LPS), and concanavalin A. Results: Conditional ablation of c-FLIP in hepatocytes augmented liver injury and cell death in all three models of liver injury. CD95- and GalN/LPS-induced liver injury was ameliorated by a pancaspase inhibitor, while ConA-induced injury was unaffected by caspase inhibition. Augmented activation of the MAPK JNK was observed in parallel to liver injury in c-FLIP knockout mice in all injury models; however, inhibition of JNK only affected TNF- and ConA-mediated injury. Conclusions: In summary, c-FLIP is a central regulator of cell death in hepatocytes, involving increased activation of caspases and the MAPK JNK. [ABSTRACT FROM AUTHOR]
- Published
- 2011
- Full Text
- View/download PDF
24. Hepatocyte-specific deletion of IL1-RI attenuates liver injury by blocking IL-1 driven autoinflammation.
- Author
-
Gehrke, Nadine, Hövelmeyer, Nadine, Waisman, Ari, Straub, Beate K., Weinmann-Menke, Julia, Wörns, Marcus A., Galle, Peter R., and Schattenberg, Jörn M.
- Subjects
- *
HEPATOCYTE growth factor , *CYTOKINES , *MICROGLIA , *IMMUNE response , *LABORATORY mice - Abstract
Background & Aims Interleukin (IL)-1-type cytokines including IL-1α, IL-1β and interleukin-1 receptor antagonist (IL-1Ra) are among the most potent molecules of the innate immune system and exert biological activities through the ubiquitously expressed interleukin-1 receptor type 1 (IL-1R1). The role of IL-1R1 in hepatocytes during acute liver failure (ALF) remains undetermined. Methods The role of IL-1R1 during ALF was investigated using a novel transgenic mouse model exhibiting deletion of all signaling-capable IL-1R isoforms in hepatocytes ( Il1r1 Hep−/− ). Results ALF induced by D-galactosamine (D-GalN) and lipopolysaccharide (LPS) was significantly attenuated in Il1r1 Hep−/− mice leading to reduced mortality. Conditional deletion of Il1r1 decreased activation of injurious c-Jun N-terminal kinases (JNK)/c-Jun signaling, activated nuclear factor-kappa B (NF-κB) p65, inhibited extracellular signal-regulated kinase (ERK) and prevented caspase 3-mediated apoptosis. Moreover, Il1r1 Hep−/− mice exhibited reduced local and systemic inflammatory cytokine and chemokine levels, especially TNF-α, IL-1α/β, IL-6, CC-chemokine ligand 2 (CCL2), C-X-C motif ligand 1 (CXCL-1) and CXCL-2, and a reduced neutrophil recruitment into the hepatic tissue in response to injury. NLRP3 inflammasome expression and caspase 1 activation were suppressed in the absence of the hepatocellular IL-1R1. Inhibition of IL-1R1 using IL-1ra ( anakinra ) attenuated the severity of liver injury, while IL-1α administration exaggerated it. These effects were lost ex vivo and at later time points, supporting a role of IL-1R1 in inflammatory signal amplification during acute liver injury. Conclusion IL-1R1 in hepatocytes plays a pivotal role in an IL-1-driven auto-amplification of cell death and inflammation in the onset of ALF. Lay summary Acute liver injury which can cause lethal liver failure is medicated by a class of proteins called cytokines. Among these, interleukin-1 (IL-1) and the corresponding receptor IL-1R1 play a prominent role in the immune system, but their role in the liver is undetermined. In the current study, a novel mouse model with defective IL-1R1 in liver cells was studied. Mice lacking this receptor in liver cells were protected from cell death to a certain extent. This protection occurred only in the presence of other, neighboring cells, arguing for the involvement of proteins derived from these cells. This effect is called paracrine signaling and the current study has for the first time shown that the IL-1R1 receptor on hepatocytes is involved in acute liver failure in this context. The approved drug anakinra – which blocks IL-1R1 – had the same effect, supporting the proposed mechanism of action. The findings of this study suggest new treatment options for patients with acute liver failure by blocking defined signals of the immune system. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
25. The treatment of intermediate stage tumours beyond TACE: From surgery to systemic therapy.
- Author
-
Galle, Peter R., Tovoli, Francesco, Foerster, Friedrich, Wörns, Marcus A., Cucchetti, Alessandro, and Bolondi, Luigi
- Subjects
- *
LIVER cancer , *CHEMOEMBOLIZATION , *LIVER function tests , *TUMOR classification , *NECROSIS , *PREVENTION - Abstract
Summary Treatment of hepatocellular carcinoma (HCC) is dependent on the stage of the disease. Intermediate stage HCC encompasses the largest subgroup of patients with the disease, and is characterized by substantial heterogeneity. The standard therapeutic approach, transarterial chemoembolization (TACE), is probably over-used and may not be appropriate for all patients with intermediate stage HCC. In patients with extensive tumour bulk, multi-nodular spread or impaired liver function, TACE may not be optimal and other treatments can be considered as a first-line treatment. These include surgery, percutaneous ablation, radioembolization or systemic treatment. In addition, patients who do not achieve complete or partial necrosis (TACE failure) and patients with early recurrence after TACE, should be managed individually, considering systemic treatments usually reserved for advanced disease. In selected cases and in patients who achieve downstaging, radical approaches such as hepatic resection or even liver transplantation can be considered. In this review, we evaluate the current literature for the treatment strategies for patients with intermediate Barcelona Clinic Liver Cancer (BCLC) B stage HCC. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
26. Resminostat plus sorafenib as second-line therapy of advanced hepatocellular carcinoma – The SHELTER study.
- Author
-
Bitzer, Michael, Horger, Marius, Giannini, Edoardo G., Ganten, Tom M., Wörns, Marcus A., Siveke, Jens T., Dollinger, Matthias M., Gerken, Guido, Scheulen, Max E., Wege, Henning, Zagonel, Vittorina, Cillo, Umberto, Trevisani, Franco, Santoro, Armando, Montesarchio, Vincenzo, Malek, Nisar P., Holzapfel, Julia, Herz, Thomas, Ammendola, Astrid S., and Pegoraro, Stefano
- Subjects
- *
LIVER cancer , *PHARMACOKINETICS , *SORAFENIB , *DEACETYLASES , *ZINC-finger proteins - Abstract
Background & Aims No established therapies for patients with hepatocellular carcinoma (HCC) and progression on first-line sorafenib treatment currently exist. This phase I/II trial investigated safety, pharmacokinetics and potential biomarkers of the histone deacetylase inhibitor resminostat and a combination therapy with resminostat and sorafenib. Methods Patients with HCC and radiologically confirmed progression on sorafenib were treated in an exploratory, multi-center, open-label, uncontrolled, non-randomized, parallel group phase I/II study. In the combination group (n = 38) four dose levels ranged from daily 200 to 600 mg resminostat plus 400 to 800 mg sorafenib. The monotherapy group (n = 19) received 600 mg resminostat. Results 57 patients received treatment. Most common adverse events were gastrointestinal disorders, thrombocytopenia and fatigue. Median maximal histone deacetylase inhibition and highest increase in H4-acetylation matched T max of resminostat. Sorafenib or the Child-Pugh score did not affect typical pharmacokinetics characteristics of resminostat. Efficacy assessment as progression-free survival-rate after 6 treatment cycles (12 weeks, primary endpoint) was 12.5% for resminostat and 62.5% for resminostat plus sorafenib. Median time to progression and overall survival were 1.8 and 4.1 months for resminostat and 6.5 and 8.0 months for the combination, respectively. Zinc finger protein 64 (ZFP64) baseline expression in blood cells was found to correlate with overall survival. Conclusions The combination of sorafenib and resminostat in HCC patients was safe and showed early signs of efficacy. Sorafenib did not alter the pharmacokinetic profile of resminostat or its histone deacetylase inhibitory activity in vivo . A prognostic and potentially predictive role of ZFP64 for treatment with resminostat should be further investigated in HCC and possibly other cancer indications. Lay summary No established therapy for patients with advanced hepatocellular carcinoma and progression under first-line systemic treatment with sorafenib currently exists. Epigenetic modulation by inhibition of histone deacetylases might be able to overcome therapy resistance. This exploratory phase I/II clinical study in patients with radiologically confirmed progression under first-line treatment with sorafenib investigated the histone deacetylases inhibitor resminostat as single agent or in combination with continued application of sorafenib. Clinical trial registration The clinical trial has been registered at www.clinicaltrials.gov as NCT00943449. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
27. Liver specific deletion of CYLDexon7/8 induces severe biliary damage, fibrosis and increases hepatocarcinogenesis in mice
- Author
-
Urbanik, Toni, Boger, Regina Johanna, Longerich, Thomas, Becker, Katharina, Ehrenberg, Karl Roland, Hövelmeyer, Nadine, Hahn, Matthias, Schuchmann, Marcus, Jäger, Dirk, Waisman, Ari, Wörns, Marcus Alexander, and Schulze-Bergkamen, Henning
- Subjects
- *
LIVER diseases , *BILIOUS diseases & biliousness , *FIBROSIS , *LIVER cancer , *LABORATORY mice , *NF-kappa B - Abstract
Background & Aims: CYLD is a tumor suppressor gene that is mutated in familial cylindromatosis, an autosomal dominant predisposition to tumors of skin appendages. Reduced CYLD expression has been observed in other tumor entities, including hepatocellular carcinoma. In the present study, we analyzed the role of CYLD in liver homeostasis and hepatocarcinogenesis in vivo. Methods: Mice with liver-specific deletion of CYLDexon7/8 (CYLDFFxAlbCre) were generated. Liver tissues were histologically analyzed and oval cell activation was investigated. Hepatocarcinogenesis was induced by diethylnitrosamine/phenobarbital (DEN/PB). Microarray expression profiling of livers was performed in untreated as well as DEN/PB-treated mice. NF-κB signaling was assessed by ELISA, quantitative real-time PCR, and Western blotting. Results: CYLDFFxAlbCre hepatocytes and cholangiocytes did not express full-length CYLD (FL-CYLD) protein but showed increased expression of the naturally occurring short-CYLD splice variant (s-CYLD). CYLDFFxAlbCre mice exhibited a prominent biliary phenotype with ductular reaction and biliary-type fibrosis. In addition, CYLDFFxAlbCre mice showed a significantly increased sensitivity towards DEN/PB-induced hepatocarcinogenesis. Moreover, we could observe the development of cholangiocellular carcinoma, in line with enhanced oval cell activity. NF-κB-signaling was increased in livers of CYLDFFxAlbCre mice and likely contributed to the inflammatory and fibrotic response. Conclusions: The deletion of exon7/8 of the CYLD gene activates oval cells, leads to a biliary phenotype, and increases the susceptibility towards carcinogenesis in the liver. Thus, our study presents a novel model of biliary damage and liver fibrosis, followed by cancer development. [ABSTRACT FROM AUTHOR]
- Published
- 2012
- Full Text
- View/download PDF
28. A systems biology perspective on cholangiocellular carcinoma development: Focus on MAPK-signaling and the extracellular environment
- Author
-
Wang, Chunxia, Maass, Thorsten, Krupp, Markus, Thieringer, Florian, Strand, Susanne, Wörns, Marcus A., Barreiros, Ana-Paula, Galle, Peter R., and Teufel, Andreas
- Subjects
- *
CHOLANGIOCARCINOMA , *SYSTEMS biology , *TUMOR growth , *CELLULAR signal transduction , *PATHOLOGICAL physiology , *MEDICAL publishing , *CELL cycle , *BIOINFORMATICS , *GENETICS - Abstract
Background/Aims: Multiple genes have been implicated in cholangiocellular carcinoma (CCC) development. However, the overall neoplastic risk is likely associated with a much lower number of critical physiological pathways. Methods: To investigate this hypothesis, we extracted all published genetic associations for the development of CCC from PubMed (genetic association studies, but also studies associating genes and CCC in general, i.e. functional studies in cell lines, genetic studies in humans, knockout mice etc.) and integrated CCC microarray data. Results: We demonstrated the MAPK pathway was consistently enriched in CCC. Comparing our data to genetic associations in HCC often successfully treated by a multityrosine kinase inhibitor, sorafenib, we demonstrated a similar overrepresentation of MAPK. In contrast, most cancer-related genetic studies focusing on genes related to transcription and cell cycle control, we consistently found genes coding for products in the extracellular environment to be significantly enriched. Thus, CCC must be regarded as developing in the context of an altered extracellular environment. Conclusions: Our study suggests the liver microenvironment holds essential functions and structures key to CCC progression. Furthermore, we identified the MAPK signaling pathway consistently enriched, pointing towards a critical role in CCC development. These data may provide a rationale for treatment of CCC with sorafenib. [Copyright &y& Elsevier]
- Published
- 2009
- Full Text
- View/download PDF
29. SAT-069-Interleukin 6: A marker for hepatic encephalopathy.
- Author
-
Labenz, Christian, Huber, Yvonne, Michael, Nagel, Marquardt, Jens, Galle, Peter, Jörn, PD Dr. Schattenberg, and Wörns, Marcus-Alexander
- Subjects
- *
HEPATIC encephalopathy , *CIRRHOSIS of the liver , *INTERLEUKIN-6 , *BIOMARKERS , *DISEASE risk factors - Published
- 2019
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.